SciLicium is an innovative company specialized in bioinformatics applied to dermatology, cosmetics, and toxicology. Based in Rennes, SciLicium designs and develops solutions for the processing, analysis, and visualization of high-throughput transcriptomic data (bulk RNA-seq, single-cell, spatial), leveraging a unique expertise in toxicogenomics, in vitro modeling, and artificial intelligence.
The company supports stakeholders in the healthcare, biotechnology, and cosmetic industries in evaluating the safety and efficacy of their products by combining multi-omics analysis with custom software development. Its flagship products include OmicSkin (transcriptomic evaluation of cosmetic effects), GenoLens (multi-project dashboard), and TOXsIgN (transcriptomic signature comparison).
Find out more about SciLicium: scilicium.com
WHY JOIN ATLANPOLE BIOTHERAPIES ?
“SciLicium joins Atlanpole Biotherapies to engage deeply with the regional health-biotech ecosystem, strengthen collaborations in toxicogenomics and high-content transcriptomics, and accelerate the development of innovative solutions for dermatology, cosmetics, and precision medicine. The cluster is a strategic catalyst for visibility, partnerships, and innovation.” Thomas Darde, CEO.